ClariTrial | Search Clinical Trials

Phase 3Mitochondrial DiseasesMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)

SonlicromanolPlacebo

Khondrion BV220 participants10 sites · United States, Denmark, FranceCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2

Phase 2Ventricular TachycardiaArrythmia, Cardiac

Stereotactic Arrhythmia Radiotherapy

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)12 participants1 site · NetherlandsCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Phase 3High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular Risk

ZilebesiranPlacebo

Alnylam Pharmaceuticals11,000 participants1105 sites · United States, Argentina, AustraliaCompletes Sep 2030

Compare CT.gov Full analysis →

Recruiting

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Phase 2Phase 3Empagliflozin in Cardiorenal Syndrome Type 1

Empagliflozin 10 MGPlacebo

Chulalongkorn University200 participants1 site · ThailandCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

Phase 3Coronary Artery DiseasePercutaneous Coronary InterventionAcute Coronary Syndromes

ClopidogrelTicagrelorPrasugrel

Cardiocentro Ticino355 participants1 site · SwitzerlandCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Phase 3Cardiovascular Disease and Lipoprotein(a)

Pelacarsen (TQJ230)

Novartis Pharmaceuticals5,700 participants643 sites · United States, Argentina, AustraliaCompletes Jan 2030

Compare CT.gov Full analysis →

Recruiting

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Phase 1Phase 2Malignant Digestive System Neoplasm

Biospecimen CollectionCapecitabineDiltiazem Hydrochloride+7 more

Mayo Clinic60 participants1 site · United StatesCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow

Phase 3ST Segment Elevation Myocardial Infarction (STEMI)No Reflow Phenomenon

Adrenaline

Ain Shams University1,000 participants1 site · EgyptCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

Phase 1Phase 2SARS-CoV-2Influenza, HumanRespiratory Syncytial Virus Infections

Placebo comparatorPRS CK STORMPRS CK STORM

PEACHES BIOTECH50 participants3 sites · SpainCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants

Phase 2Patent Ductus Arteriosus After Premature Birth

Acetaminophen InjectionIbuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)Sodium chloride 0.9% injection

Mount Sinai Hospital, Canada310 participants9 sites · Australia, Canada, Hong KongCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

Phase 3Acute Ischemic StrokeAtrial Fibrillation

Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)Usual care for atrial fibrillation

Universitätsklinikum Hamburg-Eppendorf1,746 participants1 site · GermanyCompletes Jul 2031

Compare CT.gov Full analysis →

Recruiting

NO During CPB in Neonates to Reduce Risk of AKI

Phase 3AKICHD - Congenital Heart DiseaseSurgery

Nitric OxideOxygen

Children's Hospital Medical Center, Cincinnati40 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

1–15 of 585

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

585 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 39

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Phase 1Phase 2Myocardial IschemiaCoronary Artery Disease

Regadenoson

GE Healthcare54 participants5 sites · France, Greece, ItalyCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

Phase 3NSTEMI - Non-ST Segment Elevation MISTEMI (ST Elevation MI)Myocardial Infarction

Ticagrelor + placeboTicagrelor + aspirin

Montreal Heart Institute2,570 participants1 site · CanadaCompletes Jan 2030

Compare CT.gov Full analysis →

Recruiting

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Phase 3Acute Coronary Syndrome

DalcetrapibPlacebo

DalCor Pharmaceuticals2,000 participants231 sites · United States, Canada, Puerto RicoCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

Phase 3Mitochondrial DiseasesMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)

SonlicromanolPlacebo

Khondrion BV220 participants10 sites · United States, Denmark, FranceCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2

Phase 2Ventricular TachycardiaArrythmia, Cardiac

Stereotactic Arrhythmia Radiotherapy

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)12 participants1 site · NetherlandsCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Phase 3High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular Risk

ZilebesiranPlacebo

Alnylam Pharmaceuticals11,000 participants1105 sites · United States, Argentina, AustraliaCompletes Sep 2030

Compare CT.gov Full analysis →

Recruiting

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Phase 2Phase 3Empagliflozin in Cardiorenal Syndrome Type 1

Empagliflozin 10 MGPlacebo

Chulalongkorn University200 participants1 site · ThailandCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

Phase 3Coronary Artery DiseasePercutaneous Coronary InterventionAcute Coronary Syndromes

ClopidogrelTicagrelorPrasugrel

Cardiocentro Ticino355 participants1 site · SwitzerlandCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Phase 3Cardiovascular Disease and Lipoprotein(a)

Pelacarsen (TQJ230)

Novartis Pharmaceuticals5,700 participants643 sites · United States, Argentina, AustraliaCompletes Jan 2030

Compare CT.gov Full analysis →

Recruiting

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Phase 1Phase 2Malignant Digestive System Neoplasm

Biospecimen CollectionCapecitabineDiltiazem Hydrochloride+7 more

Mayo Clinic60 participants1 site · United StatesCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

Phase 3ST Segment Elevation Myocardial Infarction (STEMI)No Reflow Phenomenon

Adrenaline

Ain Shams University1,000 participants1 site · EgyptCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

Phase 1Phase 2SARS-CoV-2Influenza, HumanRespiratory Syncytial Virus Infections

Placebo comparatorPRS CK STORMPRS CK STORM

PEACHES BIOTECH50 participants3 sites · SpainCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants

Phase 2Patent Ductus Arteriosus After Premature Birth

Acetaminophen InjectionIbuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)Sodium chloride 0.9% injection

Mount Sinai Hospital, Canada310 participants9 sites · Australia, Canada, Hong KongCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE

Phase 3Acute Ischemic StrokeAtrial Fibrillation

Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)Usual care for atrial fibrillation

Universitätsklinikum Hamburg-Eppendorf1,746 participants1 site · GermanyCompletes Jul 2031

Compare CT.gov Full analysis →

Recruiting

NO During CPB in Neonates to Reduce Risk of AKI

Phase 3AKICHD - Congenital Heart DiseaseSurgery

Nitric OxideOxygen

Children's Hospital Medical Center, Cincinnati40 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

1–15 of 585